Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $48.10 is 281.75% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 48.55||$ 62.83|
|Low:||$ 47.35||$ 12.60|
ETFs with MYOK as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|1.53%||SPDR S&P Pharmaceuticals ETF (XPH)||-1.90 (-4.11%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
MyoKardia, Inc. (the "Company"), incorporated under the laws of the State of Delaware in 2012, is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to discover and develop a pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy--hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM, both of which are chronic and debilitating diseases. Our proprietary, orally administered small molecules target the biomechanical defects that cause disruptions in heart muscle contraction. ... More ...
Nasdaq Official Price
Jun. 19, 2018
Jun. 19, 2018